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Objective. Studies suggest that rheumatoid arthritis (RA)-related autoimmunity is initiated at a mucosal site. However, the factors associated with the mucosal generation of this autoimmunity are unknown, especially in individuals who are at risk of future RA. Therefore, we tested anti-cyclic citrullinated peptide (anti-CCP) antibodies in the sputum of RA-free first-degree relatives (FDRs) of RA patients and patients with classifiable RA.
Methods. We evaluated induced sputum and serum samples from 67 FDRs and 20 RA patients for IgA anti-CCP and IgG anti-CCP, with cutoff levels for positivity determined in a control population. Sputum was also evaluated for cell counts, neutrophil extracellular traps (NETs) using sandwich enzyme-linked immunosorbent assays for protein/nucleic acid complexes, and total citrulline.
Results. Sputum was positive for IgA and/or IgG anti-CCP in 14 of 20 RA patients (70%) and 17 of 67 FDRs (25%), including a portion of FDRs who were serum anti-CCP negative. In the FDRs, elevations of sputum IgA and IgG anti-CCP were associated with elevated sputum cell counts and NET levels. IgA anti-CCP was associated with ever smoking and with elevated sputum citrulline levels.
Conclusion. Anti-CCP is elevated in the sputum of FDRs, including seronegative FDRs, suggesting that the lung may be a site of anti-CCP generation in this population. The association of anti-CCP with elevated cell counts and NET levels in FDRs supports a hypothesis that local airway inflammation and NET formation may drive anti-CCP production in the lung and may promote the early stages of RA development. Longitudinal studies are needed to follow the evolution of these processes relative to the development of systemic autoimmunity and articular RA.
Seropositive rheumatoid arthritis (RA) is characterized by disease-associated autoantibodies, including antibodies to citrullinated proteins/peptides (ACPAs) that are commonly measured using anti-cyclic citrullinated peptide (anti-CCP) assays. In established RA, ACPA isotypes, including IgA and IgG, are prevalent, specific, and associated with higher levels of disease activity, suggesting that they play an important role in the pathogenesis of RA (1) (2) (3) (4) . Understanding the development of ACPA isotypes could therefore provide further insight into the cause of RA.
It is well established that ACPAs can be present for years prior to the onset of inflammatory arthritis, during a period of systemic autoimmunity associated with RA that can be called preclinical RA and can be defined as the presence of circulating RA-related autoantibodies prior to the onset of clinically apparent synovitis (2) (3) (4) (5) (6) (7) (8) (9) (10) . Importantly, individuals without classifiable RA who have circulating ACPAs do not exhibit synovitis, as assessed by physical examination (5, 11) , imaging with ultrasound or magnetic resonance (5, (11) (12) (13) , or synovial biopsy (12, 13) . These findings strongly suggest that in order to understand the initial steps in the generation of ACPAs, studies must examine individuals who have not yet developed clinically apparent synovitis and classifiable RA. These data also indicate that ACPAs originate at a site outside the joint.
As to where that site is, emerging data support the hypothesis that ACPAs may be initially generated at a mucosal surface (2) (3) (4) (5) (14) (15) (16) (17) (18) (19) (20) . For example, serum levels of IgA ACPAs are elevated in populations who are at risk of developing RA, including first-degree relatives (FDRs) of RA patients (2) (3) (4) . The strong association between smoking, lung disease, and ACPA-positive RA further support the idea that the lung mucosa may be a particularly relevant site of ACPA generation (17) (18) (19) . In addition, our group previously demonstrated that circulating RA-related autoantibodies were associated with airway abnormalities in the absence of inflammatory arthritis (5) , and ACPAs were detectable in the lung of a portion of inflammatory arthritis-free FDRs, as determined by testing of induced sputum samples (14) .
While these data are intriguing, the mechanisms that trigger local ACPA production in the lung are unknown. However, understanding the factors that may drive the initial development of ACPAs and IgA ACPAs in particular, given the role of IgA in mucosal immunity, may ultimately lead to novel approaches to the prediction, treatment, and prevention of RA.
Several candidates may be potential factors associated with ACPA formation at the mucosal surface, including exposure to environmental agents such as smoking and local inflammation, which can lead to citrullination. In addition, multiple studies have suggested a role of neutrophil extracellular trap (NET) formation (or, NETosis) in RA. NETosis is a peptidylarginine deiminase type 4 (PAD4)-mediated process by which neutrophils decondense and externalize their DNA in complex with neutrophil cytoplasmic granule proteins, such as myeloperoxidase (MPO) and neutrophil elastase (NE) (21) (22) (23) . Enhanced NETosis has been associated with ACPAs peripherally and in the joints of patients with established RA (24) (25) (26) . While NET formation in sputum has been associated with lung disease (27) (28) (29) , it is unknown whether NETs are associated with ACPAs in the lung of subjects at risk of developing RA.
In order to explore factors associated with the generation of APCAs in the lung, we evaluated inflammatory arthritis-free FDRs of RA patients, who are at higher risk of developing RA. We investigated levels of isotype-specific anti-CCP as well as a variety of factors, including demographic features, environmental exposures, genetic factors, and sputum biomarkers including cell counts, total citrullination, and markers of NETosis, in induced sputum samples from FDRs.
PATIENTS AND METHODS
Study subjects. Subjects were recruited from the Studies of the Etiology of RA (SERA) cohort, which is described in detail elsewhere (30, 31) . Briefly, SERA evaluates in a prospective manner the FDRs of RA patients, with these FDRs being at elevated risk of RA based on their family history of disease (32, 33) , making them a reasonable group in which to evaluate the earliest stages of RA. For this study, SERA subjects were recruited from the Denver, CO, study site between January 2011 and October 2015.
FDRs. We recruited SERA FDRs who had no evidence of inflammatory arthritis. FDRs were not selected based on serum anti-CCP status, but as our group and others have reported, inflammatory arthritis-free FDRs have a higher prevalence of serum anti-CCP positivity compared to the general population, including 9.5% positivity for the commercially available anti-CCP-3.1 antibody (IgG/IgA; Inova Diagnostics) (3, 6) .
Patients with early RA. We recruited patients who had classifiable RA that had been diagnosed within the past 1 year and were seropositive for anti-CCP-3.1. RA patients were recruited sequentially from rheumatology clinics or from SERA research study visits if a subject developed incident inflammatory arthritis that met classification criteria during prospective follow-up. RA was confirmed by medical chart review, and all patients met the American College of Rheumatology/European League Against Rheumatism 2010 classification criteria (34) .
Healthy control subjects. In order to determine cutoff levels for anti-CCP isotype positivity, we recruited healthy control subjects from the community through local advertisements, seeking those who were serum anti-CCP-3.1 negative, did not have RA or inflammatory arthritis, and did not have an FDR with RA.
All study procedures were approved by the Colorado Multiple Institutional Review Board. Informed consent was obtained from all study subjects.
Study visit. All study subjects underwent collection of paired samples of blood and sputum on the same day, except for 3 subjects, who had sputum collected within 2 weeks of blood samples. Subjects without RA underwent a joint-focused interview and examination of 66 joints by a trained rheumatologist (MKD, LBK, or KDD) to assure that there was no clinically evident inflammatory arthritis. Standardized questionnaires were used to obtain demographic information and self-reported histories of smoking and chronic lung disease.
Genetic testing. Blood was tested for the presence of alleles containing the shared epitope (SE) using previously described methods (30) . The following alleles were considered to contain the SE: DRB1*04:01, 04:04, 04:05, 04:08, 04:09, 04:10, and DR1 01:01 and 01:02.
Sputum collection. Induced sputum was collected and processed using established protocols, which are described in detail elsewhere (14) . Briefly, sputum samples were collected over 15 minutes using hypertonic nebulized saline. The entire sputum sample was diluted with phosphate buffered saline (PBS), followed by syringe-based mechanical homogenization. Samples collected after September 2013 underwent manual cell counts, with differential cell counts performed using a hemocytometer and cytocentrifugation. Cell counts were reported as the number 3 10 4 /ml. To minimize salivary contamination of sputum samples, subjects underwent oral wash prior to sputum collection. In addition, per established methods, subjects were asked to spit any saliva during the sputum collection into a separate plastic container, and they were instructed to only use the sputum collection cup when producing a sputum sample from coughing (35) . Only samples that were consistent with lower airways origin, as demonstrated by ,10 squamous epithelial cells/high-power field on light microscopy or ,80% squamous epithelial cells on cell differential (35, 36) , were used for the analyses.
After homogenization, samples were centrifuged and proteinase inhibitors (phenylmethylsulfonyl fluoride) and EDTA were added to the supernatant. A mucolytic agent, such as dithiothreitol, was not used so as to avoid the destruction of disulfide bonds that could affect antibody structure and conformation. All sputum biomarker testing was performed on the cell-free supernatants, except for the cell count and differential cell count, which were performed prior to centrifugation. Because sputum testing was performed on diluted samples, all sputum results reported herein have been multiplied by the sample's dilution factor, which was calculated based on the amount of PBS added and the original weight of the sample.
Serum and sputum testing for IgA and IgG anti-CCP. Serum and sputum samples underwent enzyme-linked immunosorbent assay (ELISA) for IgA anti-CCP and IgG anti-CCP at the University of Colorado Division of Rheumatology Clinical Research Laboratory, using a CCP-3 plate and the respective conjugate (for research only; Inova Diagnostics). A positive control sample was provided by the manufacturer for each isotype. The levels in sputum and serum are reported as relative units based on the optical density (OD) of the test sample divided by the OD of the positive control. This approach allowed us to account for any plate-to-plate variation. Cutoff levels for positivity of the anti-CCP isotypes were set at a level that was present in ,5% of our healthy control subjects, thereby corresponding to a level at or above the 95th percentile in controls. Of note, anti-CCP isotype cutoff levels for both serum and sputum were set using the same control group.
In this study, serum and sputum anti-CCP levels were measured in duplicate wells. For sputum, the mean coefficient of variation between wells was 4.8% for IgA anti-CCP and 5.3% for IgG anti-CCP. To further validate the anti-CCP isotype assays, we tested serum from 6 subjects without RA, 3 of whom were previously found to have high anti-CCP isotype levels and 3 had low levels. We determined intraassay variability for each isotype by testing serum from each subject in 10 wells each. The mean coefficient of variation was 8.4% for IgA anti-CCP and 8.0% for IgG anti-CCP.
Total Ig testing. In subjects with adequate sputum volume available after anti-CCP testing, the levels of total IgA and IgG (in mg/dl) were also tested in the sputum (Siemens BN II nephelometry cerebrospinal fluid assessment system) and serum (Beckman-Coulter Synchron nephelometry system).
NET levels. In samples collected prior to January 2015 that had adequate sputum volume following anti-CCP and Ig testing, the level of NETosis was measured as NET remnants in cell-free supernatant of sputum. Specifically, NET-associated protein-nucleic acid complexes were quantified using a sandwich ELISA that detects complexes of DNA-MPO and DNA-NE, as previously described (37), and as follows: for DNA-MPO complexes, high-binding 96-well ELISA microplates were incubated overnight at 48C with mouse anti-human MPO (clone 4A4; AbD Serotec) in coating buffer from a Cell Death Detection ELISA kit (Roche). After blocking with 1% bovine serum albumin, plates were incubated overnight at 48C with 10% sputum in blocking buffer, washed and peroxidase-conjugated anti-DNA (Roche) was added for 1.5 hours at room temperature. Tetramethylbenzidine substrate (Sigma) was then added, and absorbance was measured at 450 nm after addition of stop reagent (Sigma).
The methods for the DNA-NE complexes were similar as those for the DNA-MPO complexes. The antibody used to coat plates was rabbit anti-human NE (Calbiochem). After overnight incubation with sputum, plates were incubated for 1 hour at room temperature with mouse anti-double-stranded DNA monoclonal antibody (Millipore), followed by horseradish peroxidase-conjugated anti-mouse IgG (Bio-Rad). The procedure was then completed as for the DNA-MPO complexes.
Total citrulline content. In sputum samples that were tested for NETs, the total citrulline level was quantified (in nmoles/ml) using the detection step of the Color Development Reagent assay and quantified as previously described (38) (39) (40) . To avoid detection of urea and methylurea with this assay, a 20-fold excess of urease was added to each sputum sample for 15 minutes at 258C prior to testing.
Statistical analysis. Prevalence of positivity was compared between groups using chi-square/Fisher's exact test and within groups using McNemar's test. Because of a non-normal distribution of anti-CCP isotype levels, nonparametric testing was used to compare anti-CCP levels across groups (MannWhitney U test) and to perform correlation analyses between anti-CCP levels and other factors (Spearman's correlation coefficient). In addition, linear regression was used to evaluate the relationship between sputum anti-CCP levels and sputum cell counts as well as between NET and citrulline levels, accounting for adjustment variables when necessary. We report the T statistic and P value for each relationship. In these linear models, sputum anti-CCP levels and cell counts were log-transformed to meet the assumption of normality for linear regression. The potential confounders of age, sex, ever smoking, SE positivity, and citrulline level were included in the models and were removed at a level of a . 0.10.
Analyses were performed using SPSS (version 23) and SAS (version 9.4). Figures were generated in GraphPad Prism (version 7).
RESULTS
Characteristics of the study subjects. We evaluated 67 FDRs, 20 RA patients, and 70 healthy control subjects. The characteristics of these subjects are shown in Table 1 . There was no statistically significant difference in age, sex, presence of $1 SE allele, history of ever smoking, or chronic lung disease between the FDRs and the RA patients. RA patients were more likely to be current smokers and less likely to be nonHispanic white. Compared to the FDRs and RA patients, the controls were younger, less likely to be smokers, and less likely to be SE positive.
Sputum IgA and IgG anti-CCP positivity in FDRs and RA patients. Seventeen of the 67 FDRs (25.4%) had IgA anti-CCP and/or IgG anti-CCP in their sputum ( Figure 1 , and because this group was used to establish cutoff values, these subjects were not studied relative to the FDR or RA populations. ** The presence of chronic lung disease was determined by self-report using a questionnaire that asked whether subjects had a health care provider-diagnosed history of asthma, emphysema, chronic bronchitis, bronchiectasis, interstitial lung disease, lung cancer, pulmonary artery hypertension, obstructive sleep apnea, or other chronic lung disease. Figures 1A and B) .
When comparing rates of autoantibody positivity within groups, the rates of sputum IgG anti-CCP positivity were higher than IgA anti-CCP in the RA patients the RA patients, 13 were serum IgA anti-CCP positive, of whom 8 (62%) were also sputum IgA anti-CCP positive, and 7 were serum IgA anti-CCP negative, of whom none were sputum IgA anti-CCP positive (Supplementary Figure 1C ). In addition, there were 19 serum IgG anti-CCP-positive RA patients, of whom 13 (68%) were also sputum IgG anti-CCP positive, and there was 1 serum IgG anti-CCP-negative RA patient who was sputum IgG anti-CCP positive (Supplementary Figure 1D) .
To evaluate the potential for translocation of anti-CCP from serum to sputum, we compared the ratios of anti-CCP to total Ig levels for each isotype in sputum and serum, with the rationale that a higher ratio at one site supports the idea that the antibody is generated at that site (41, 42) . In the sputum anti-CCPpositive FDRs, 11 of 14 (79%) had a higher ratio of IgA anti-CCP to total IgA in the sputum compared to the serum, and 9 of 10 (90%) had a higher ratio of IgG anti-CCP to total IgG in the sputum, which supports the notion that the anti-CCP was generated in the lung in the majority of these subjects. In the sputum anti-CCPpositive RA patients, 3 of 8 (38%) had a higher ratio of IgA anti-CCP to total IgA in the sputum, and 11 of 13 (85%) had a higher ratio of IgG anti-CCP to total IgG in the sputum. In addition, the median total IgA and IgG levels in sputum did not differ between the FDRs and the RA patients, but the total sputum IgA levels in both groups was higher than that in the controls (Supplementary Figure 2 , available at http://onlinelibrary. wiley.com/doi/10.1002/art.40066/abstract).
Comparison of subject characteristics and sputum anti-CCP isotypes. Because smoking has been associated with an increased risk of serum anti-CCPpositive RA and is relevant in sputum studies (17), we analyzed subjects stratified by smoking history. In the FDRs, sputum IgA, but not IgG, anti-CCP positivity was significantly higher in ever smokers compared to never smokers (Figures 1C and D) . A similar, but not significant, association was seen in the RA patients In the FDRs, there were no associations between sputum IgA or IgG anti-CCP positivity and sex, race, $1 SE allele, or history of lung disease (data not shown). Correlation analysis did not identify a significant correlation between age and sputum anti-CCP isotype levels.
Similarly, in RA patients and control subjects, there were no significant correlations or associations between sputum anti-CCP isotypes and age, sex, race, SE positivity, or history of lung disease (data not shown).
Sputum cell counts and sputum anti-CCP isotypes. The known predominant cell types in sputum are neutrophils and macrophages (35, 36) , and we focused our analyses on these cell types. In the FDRs, there was a median of 12. Using regression analyses, we evaluated the association of anti-CCP levels with signs of airway inflammation as measured by sputum total cell counts (excluding squamous epithelial cells), and neutrophil and macrophage counts. In the FDRs, sputum IgA anti-CCP was significantly associated with total (t 5 3.5, P 5 0.001), neutrophil (t 5 3.2, P 5 0.003), and macrophage (t 5 2.9, P 5 0.006) counts (Figure 2 ). Similar associations were demonstrated for sputum IgG anti-CCP and total (t 5 1.8, P 5 0.080), neutrophil (t 5 2.5, P 5 0.018), and macrophage (t 5 2.0, P 5 0.048) counts in this group of subjects (Figure 3) . In RA patients, sputum IgA anti-CCP was significantly associated with the total cell count (t 5 2.3, P 5 0.039), but no other significant associations were seen between sputum IgA or IgG anti-CCP levels and cell counts in these patients (data not shown). Relationship between sputum IgA anti-cyclic citrullinated peptide (anti-CCP) levels and sputum cell counts in rheumatoid arthritisfree first-degree relatives. Log-transformed levels of the sputum total cell count (A), total neutrophil count (B), and total macrophage count (C) are plotted against the log-transformed levels of sputum IgA anti-CCP. P values were calculated using linear regression.
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DEMORUELLE ET AL Sputum neutrophil and macrophage counts were higher in sputum anti-CCP isotype-positive FDRs compared to sputum anti-CCP isotype-negative healthy controls, with a median neutrophil count of 43.8 3 10 4 /ml (IQR 7.6-85.5 3 10 4 /ml) versus 9.2 3 10 4 /ml (IQR 3.9-31.8 3 10 4 /ml) (P 5 0.14) and a median macrophage count of 56.9 3 10 4 /ml (IQR 20.5-240.5 3 10 4 /ml) versus 17.2 3 10 4 /ml (IQR 6.7-41.5 3 10 4 /ml) (P , 0.01). However, sputum levels of neutrophils and macrophages were similar in sputum anti-CCP isotypenegative FDRs and controls (P 5 0.69 and P 5 0.58, respectively). Relationship between sputum IgG anti-cyclic citrullinated peptide (anti-CCP) levels and sputum cell counts in rheumatoid arthritisfree first-degree relatives. Log-transformed levels of the sputum total cell count (A), total neutrophil count (B), and total macrophage count (C) are plotted against the log-transformed levels of sputum IgG anti-CCP. P values were calculated using linear regression.
Sputum NET levels and sputum anti-CCP isotypes. We next studied the association between sputum levels of anti-CCP and NETs. Using log-transformed anti-CCP levels, sputum levels of IgA and IgG anti-CCP in the FDRs were significantly associated with sputum levels of NETs, as determined by measuring DNA-MPO and DNA-NE complexes (Figure 4) . In analyses adjusting for ever smoking and citrulline levels, the association between sputum IgA anti-CCP and NET levels in the FDRs remained significant (by DNA-MPO complexes, t 5 3.75, P , 0.01; by DNA-NE complexes, t 5 2.10, P 5 0.04). In particular, for every 1-unit increase in NET level as measured by DNA-MPO complexes, there was an increase of 1.20 (95% confidence interval [95% CI] 1.09-1.33) in sputum IgA anti-CCP levels and 1.13 (95% CI 1.07-1.18) in sputum IgG anti-CCP. Similarly, for every 1-unit increase in NET level as measured by DNA-NE complexes, there was an increase of 1.17 (95% CI 1.01-1.37) in sputum IgA anti-CCP and 1.09 (95% CI 1.00-1.18) in sputum IgG anti-CCP. No significant associations between sputum IgA or IgG anti-CCP levels and NET levels were found in RA patients (data not shown).
Sputum citrulline levels and sputum anti-CCP isotypes. In the FDRs, there was a significant association between sputum citrulline and sputum IgA anti-CCP levels (t 5 3.2, P , 0.01), but not between sputum citrulline and sputum IgG anti-CCP (t 5 0.7, P 5 0.50). Sputum citrulline levels were higher in ever smokers compared to never smokers, but in analyses adjusted for ever smoking, sputum IgA anti-CCP remained significantly associated with the total citrulline level (t 5 2.7, P , 0.01). In the RA patients, there were no significant associations between sputum IgA or IgG anti-CCP levels and total citrulline levels (data not shown).
Of note, as presented in Supplementary Figure 4 (available at http://onlinelibrary.wiley.com/doi/10.1002/ art.40066/abstract), due to sample volume restrictions, a subset of 51 FDRs and 9 RA patients had sufficient sputum volume available for testing of NET and citrulline levels. To ensure that there was no selection bias in the subjects who had larger volumes of sputum, we compared FDRs and RA patients who did and did not undergo NET and citrulline testing. In these analyses, we found no significant difference in age, sex, race, SE positivity, history of ever smoking, serum anti-CCP positivity, or sputum anti-CCP positivity.
DISCUSSION
Similar to our previous work (14) but studying an expanded cohort and newly discriminating isotypespecific ACPA reactivity, we found that elevations of ACPA levels in the lung/sputum, as characterized by anti-CCP isotypes, is prevalent in a portion of FDRs (25%) and RA patients (70%). Of particular interest, this study is the first to demonstrate IgA anti-CCP in sputum, and we determined that IgA and IgG anti-CCP are associated with increased sputum cell counts and NET remnants in FDRs. Importantly, these findings provide support for the conclusion that sputum ACPA elevations are associated with local airway inflammation. This study also provides the first evidence that NET formation is associated with ACPAs in the lung, suggesting that NETosis may drive ACPA production locally in FDRs who are at an elevated risk of developing RA.
The relationship between ACPA elevations and NET formation in FDRs is of particular interest for several reasons. Elevated NETosis has been associated with established RA, can expose citrullinated proteins to the immune system, including RA-associated proteins such as citrullinated histone H3, and can release PAD4, which could citrullinate other local proteins (24) (25) (26) 43) . Although it is possible that NET formation could have been induced in our study during sputum collection or processing, this is less likely given that all samples underwent the same protocols, while elevated NET remnants were identified only in a subset. In addition, previous studies have applied immunostaining techniques that visually demonstrate the formation of NETs from sputum neutrophils (28, 29) . It will be important to understand the mechanisms contributing to higher sputum NETosis levels in these FDRs. Specific questions to be addressed are whether neutrophils from FDRs are more likely than those from non-FDRs to undergo NETosis and whether increased NETosis in the sputum can be generated by another source (e.g., microbiota, inflammatory cytokines, or ACPAs triggered by another mechanism). A recent study showed that microbial factors may affect neutrophil-related citrullination through pore-forming mechanisms (44); therefore, other mechanisms aside from NETosis by which neutrophils or other factors may contribute to mucosal citrullination need to be explored.
Because we wanted to study factors associated with the earliest steps of ACPA formation and in order to enhance our ability to find RA-related autoimmunity, we focused on FDRs as a population that is known to be at elevated risk of developing ACPAs (2, 3, 6) . It is worth noting, however, that we did not find associations between sputum ACPA isotypes and cell counts or NET levels in the RA patients. This lack of association could be due to the small number of RA patients studied or their use of immunosuppressive medications. However, 1172 DEMORUELLE ET AL it could also be that the mechanisms that drive ACPAs change during the evolution of disease or after the onset of synovitis in RA. For example, only after arthritis is present in RA have ACPAs been identified in synovial tissues (42, 45) . This will need to be explored in prospective evaluations of the evolution of sputum and serum ACPAs and other biomarkers in individuals who develop classifiable RA. Citrullination in the lung has been associated with smoking and inflammation (16, 20) . In the present study, we demonstrated that sputum IgA, but not IgG, ACPAs were associated with smoking and increased citrulline levels. Although the Color Development Reagent assay quantifies ureido groups that can include citrullinated as well as homocitrullinated peptides, this finding suggests that perhaps IgA ACPA is more likely than IgG ACPA to be formed in response to nonspecific inflammation in the lung and that other factors may be required to drive IgG ACPA formation. This finding also highlights the fact that different ACPA isotypes may play different roles in the pathogenesis of RA. Previous studies demonstrated that serum IgG ACPA positivity is higher in patients with established RA as compared to unaffected FDRs, who were more often serum IgA ACPA positive (2, 3) . In our study, we found similar associations in serum as well as sputum. Although prospective studies are needed, this finding raises the question as to whether the development of IgG ACPA is an important step in the transition from preclinical RA to clinically apparent arthritis.
We also found that a subset of FDRs demonstrated sputum ACPA isotype positivity in the absence of serum ACPA positivity. This finding further validates our previous work showing that the lung may be a site where ACPAs originate, and indeed, we have demonstrated in subset analyses that sputum IgA anti-CCP does not appear to be from a salivary source (see Supplementary Materials, available at http://onlinelibrary. wiley.com/doi/10.1002/art.40066/abstract). However, we also found some FDRs who were serum ACPA positive in the absence of sputum ACPA positivity, which suggests that in some FDRs, ACPAs may have originated at a site outside the lung. This underscores the importance of comprehensively examining additional mucosal surfaces as potential sites of initiation of RA-related autoimmunity.
While FDRs are at increased risk of developing RA-related autoimmunity, it is clear that the number of FDRs demonstrating sputum ACPA positivity exceeds the number that statistically will develop classifiable RA. This suggests that local ACPA formation may be necessary but not sufficient to progress to systemic RA-related autoimmunity and eventually arthritis. In addition, sputum ACPAs could have been translocated from the serum in the FDRs. We believe this is unlikely because many FDRs were ACPA positive only in sputum, and the ratios of Ig to anti-CCP were higher in sputum as compared to serum for the majority of FDRs. Furthermore, the primary goal in the selection of our control population was to set cutoff levels for sputum ACPA positivity. Our control subjects were younger than the FDRs or RA patients. Because there was not an association between age and ACPA level, this difference was unlikely to influence the establishment of a positive cutoff level.
Additional longitudinal studies of the prevalence and evolution of sputum ACPAs in individuals who develop classifiable RA and in carefully matched controls will be needed to better understand these issues. Specifically, studies should be conducted to validate the diagnostic accuracy of sputum ACPA isotypes for ultimate progression to classifiable RA, as well as to explore the mechanisms by which ACPA generation at a mucosal surface may occur in broader populations, perhaps as a natural response to mucosal inflammation. These latter studies are especially important if the detection of sputum autoantibodies becomes a method by which to identify subjects who may be at risk of developing RA.
Emerging data suggest that antibody reactivity to native or noncitrullinated/arginine peptides may play a role in the early development of autoimmunity in RA (19, 46, 47) . Older studies have demonstrated that in non-RA populations, serum ACPA reactivity can be nonspecific or cross-reactive with arginine peptides (48) . While our study only tested antibody reactivity to the citrullinated CCP-3 plate substrate, based on these other studies, it would be expected that a portion of our subjects could have antibodies to native proteins. Further studies are needed to address whether antibodies to native proteins precede the development of ACPAs in FDRs, whether FDRs demonstrate simultaneous generation of antibodies to citrullinated and noncitrullinated targets, and whether sputum ACPAs in FDRs are less specific and cross-react with noncitrullinated antigens.
In conclusion, ACPA isotypes as measured by anti-CCP are present in the sputum of a portion of FDRs and subjects with early classifiable disease. In FDRs, sputum ACPA is associated with elevated cell counts and NET remnants, which supports the idea that the lung plays an important role in the early phases of RA-related autoimmunity. Longitudinal and additional mechanism-based studies in broader populations are needed to further investigate this relationship.
